CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer.The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.
